Psychometric Evaluation of the Dimensional Anhedonia Rating Scale (DARS): A Preliminary Study.

IF 1.5 4区医学 Q3 CLINICAL NEUROLOGY

Journal of Nervous and Mental Disease Pub Date : 2026-09-01 Epub Date: 2026-09-07 DOI:10.1097/NMD.0000000000001894

Parker Grant, Marcos Sanches, Tony P George

{"title":"Psychometric Evaluation of the Dimensional Anhedonia Rating Scale (DARS): A Preliminary Study.","authors":"Parker Grant, Marcos Sanches, Tony P George","doi":"10.1097/NMD.0000000000001894","DOIUrl":null,"url":null,"abstract":"Aim: Anhedonia is a transdiagnostic symptom of major depressive disorder (MDD) that is also influenced by substance use, yet the Dimensional Anhedonia Rating Scale (DARS) has only been validated in MDD. This study examined the psychometric properties of the DARS in co-occurring MDD and cannabis use disorder (CUD).Methods: Thirty-five participants completed the DARS, Snaith-Hamilton Pleasure Scale (SHAPS), Hamilton Rating Scale for Depression (HRSD), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI). Analyses included confirmatory factor analysis, internal consistency, Spearman correlations, group comparisons, and ROC analysis against SHAPS-defined anhedonia.Results: The DARS supported a four-factor (and second-order) structure, demonstrated excellent internal consistency, and showed expected convergent validity (e.g., SHAPS ρ=-.64). ROC analysis indicated good discrimination (AUC=.81) with a Youden-derived threshold of 65 (sensitivity ≈.85; specificity ≈.75).Conclusions: This study provides preliminary evidence of the utility of the DARS in co-occurring MDD and CUD.","PeriodicalId":16480,"journal":{"name":"Journal of Nervous and Mental Disease","volume":" ","pages":"117-123"},"PeriodicalIF":1.5000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nervous and Mental Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/NMD.0000000000001894","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Anhedonia is a transdiagnostic symptom of major depressive disorder (MDD) that is also influenced by substance use, yet the Dimensional Anhedonia Rating Scale (DARS) has only been validated in MDD. This study examined the psychometric properties of the DARS in co-occurring MDD and cannabis use disorder (CUD).

Methods: Thirty-five participants completed the DARS, Snaith-Hamilton Pleasure Scale (SHAPS), Hamilton Rating Scale for Depression (HRSD), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI). Analyses included confirmatory factor analysis, internal consistency, Spearman correlations, group comparisons, and ROC analysis against SHAPS-defined anhedonia.

Results: The DARS supported a four-factor (and second-order) structure, demonstrated excellent internal consistency, and showed expected convergent validity (e.g., SHAPS ρ=-.64). ROC analysis indicated good discrimination (AUC=.81) with a Youden-derived threshold of 65 (sensitivity ≈.85; specificity ≈.75).

Conclusions: This study provides preliminary evidence of the utility of the DARS in co-occurring MDD and CUD.

查看原文本刊更多论文

维度快感缺乏症评定量表（DARS）的心理测量评价：初步研究。

目的：快感缺乏是重度抑郁症（MDD）的一种跨诊断症状，也受物质使用的影响，但维度快感缺乏评定量表（DARS）仅在重度抑郁症中得到验证。本研究考察了DARS在重度抑郁症和大麻使用障碍（CUD）共发中的心理测量特性。方法：35名被试完成了DARS、snath -Hamilton快乐量表（SHAPS）、Hamilton抑郁评定量表（HRSD）、Beck抑郁量表（BDI）和Beck焦虑量表（BAI）。分析包括验证性因子分析、内部一致性、Spearman相关性、组间比较和shaps定义的快感缺乏症的ROC分析。结果：DARS支持四因素（和二阶）结构，表现出良好的内部一致性，并显示预期的收敛效度（例如，SHAPS ρ=- 0.64）。ROC分析显示鉴别效果良好（AUC= 0.81），约登衍生阈值为65（敏感性≈0.85，特异性≈0.75）。结论：本研究提供了DARS在并发重度抑郁症和CUD中的应用的初步证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Nervous and Mental Disease 医学-精神病学

CiteScore

2.90

自引率

5.30%

发文量

233

审稿时长

3-8 weeks

期刊介绍： The Journal of Nervous and Mental Disease publishes peer-reviewed articles containing new data or ways of reorganizing established knowledge relevant to understanding and modifying human behavior, especially that defined as impaired or diseased, and the context, applications and effects of that knowledge. Our policy is summarized by the slogan, "Behavioral science for clinical practice." We consider articles that include at least one behavioral variable, clear definition of study populations, and replicable research designs. Authors should use the active voice and first person whenever possible.